Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib in ...

The clinical trial results of the first-ever head-to-head comparison of the first-line treatments for metastatic renal cell carcinoma (RCC) are published in this week's New England Journal of ...

In the August 22 issue, 1 we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell ...

A number of attempts at treating SCLC with targeted therapies have failed, but now there is a glimmer of hope, with positive results from a phase 2 clinical trial with sunitinib (Sutent ...

Researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma, a deadly form of kidney cancer.

An exploratory retrospective analysis of data from six key trials in patients with metastatic renal cell carcinoma (mRCC) has revealed that sunitinib has comparable efficacy regardless of patient age.

3 Sunitinib increased levels of C/EBP-α in association with downregulation of c-Myc, a negative regulator of differentiation, in MOLM13 and HL60 cells (Figure 2). Sunitinib might induce monocytic ...

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found.

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial ...

Sunitinib is recommended as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology ...